Health Canada has announced the approval of a second drug aimed at addressing the root causes of Alzheimer’s disease, a promising development for Canadian patients seeking to manage this debilitating condition. However, the high cost of the treatment raises significant questions about accessibility, particularly regarding coverage by public drug plans.
Donanemab: A New Treatment Option
On Friday, Health Canada granted approval to donanemab, marketed under the name Kisunla, a monthly intravenous therapy designed for individuals experiencing mild cognitive impairment or mild dementia stemming from Alzheimer’s. This decision comes more than two years after the agency initiated its review process in February 2024.
Donanemab belongs to a novel category of disease-modifying therapies that differ from traditional treatments, which primarily alleviate symptoms. This new drug targets beta-amyloid, a protein that accumulates in the brain and is implicated in the progression of Alzheimer’s. By clearing these harmful protein aggregates, donanemab aims to slow down cognitive decline, allowing some patients to maintain their abilities for a longer period.
The Context of Alzheimer’s Disease in Canada
Alzheimer’s disease is the leading cause of dementia, affecting approximately 770,000 Canadians. While the approval of donanemab marks a significant milestone, experts caution that it is not a cure. Both donanemab and lecanemab, another treatment approved in Canada last October, have been shown to slow down the progression of cognitive decline rather than halt it altogether.
Sharon Cohen, a behavioural neurologist and medical director at the Toronto Memory Program, expressed optimism about the approval. “This really cements the change that we see in our field,” she noted. “Treating earlier is possible. Slowing disease progression and preventing increased disability are crucial advancements.”
Financial Considerations and Access Challenges
The annual cost of donanemab is estimated at CAD 47,250, which is significantly higher than the nearly CAD 30,000 for lecanemab. This steep price tag presents a substantial barrier to access, particularly if provincial and federal drug plans choose not to cover it. In February, Canada’s Drug Agency recommended against public reimbursement for lecanemab, citing concerns over its clinical benefits and the necessity of extensive MRI monitoring for potential side effects, including brain swelling and microbleeds.
Currently, patients seeking treatment have limited options; they can either pay out-of-pocket or rely on private insurance plans. In contrast, donanemab has been approved in 48 countries worldwide, with public funding available only in a few, including the United States, China, and Japan.
A Call for Change
Christina Scicluna, CEO of the Alzheimer Society of Canada, emphasized the importance of awareness surrounding these new treatment options. “It’s crucial to understand that these drugs are not cures, nor are they intended for patients who have advanced beyond the early stages of the disease,” she stated. “However, this is not a time to remain silent. We now have disease-modifying options that did not exist before, which is a significant shift in the conversation about Alzheimer’s treatment.”
Despite the exciting prospects offered by these new therapies, the issue of affordability and access looms large.
Why it Matters
The approval of donanemab represents a potential turning point in the fight against Alzheimer’s disease in Canada, offering hope to those affected and their families. However, the challenge of securing adequate funding and access to these treatments raises critical questions about the healthcare system’s ability to support patients facing this devastating illness. As discussions around coverage and accessibility unfold, the urgency for equitable solutions has never been more pronounced.